SAN DIEGO April 4, 2019 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company’s 12-week Phase 2 study of VK2809 in….